{
  "slug": "pathogenomix",
  "name": "Pathogenomix",
  "description": "Pathogenomix provides Ripseq, a cloud-based software that converts sequencing files (Sanger, Targeted NGS, Long Reads) into clear, actionable pathogen reports. It drastically reduces identification time for infectious pathogens in pure and poly-microbial samples using novel algorithms and curated databases. Its Patho-Seq product has received FDA Breakthrough Device Designation.",
  "url": "https://optimly.ai/brand/pathogenomix",
  "websiteUrl": "https://pathogenomix.com/",
  "logoUrl": "https://logo.clearbit.com/pathogenomix.com",
  "baiScore": 57.5,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": null,
  "archetype_status": "active",
  "category": "Genomic Data Analysis Platforms",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-09-25T21:53:00.968Z",
  "verifiedVitals": {
    "website": "https://pathogenomix.com",
    "category": "Medical Diagnostics, Biotechnology",
    "what_it_does": "Pathogenomix provides SaaS online software tools and lab protocols for the rapid identification of pathogens via DNA/RNA sequencing of the pathogen's genome, turning sequencing files into clear, actionable pathogen reports. Its Ripseq sequence-based analysis identifies infectious pathogens in pure or poly-microbial samples. The company also develops Patho-Seq, an assay designed for the rapid detection and identification of hundreds of clinically relevant bacteria, which has received FDA Breakthrough Device Designation.",
    "primary_audience": "The primary audience includes research institutions, clinical laboratories, hospitals, and healthcare providers worldwide.",
    "core_product": "The core products include Ripseq (for NGS and Sanger sequence-based analysis), Ripseq DB (a curated microbial reference database), and Patho-Seq (an assay for rapid bacterial detection, currently with FDA Breakthrough Device Designation and not yet available for sale for clinical use).",
    "pricing_model": {
      "kind": "subscription",
      "detail": "Offers a 14-day free trial."
    }
  },
  "intentTags": {
    "problemIntents": [
      "Slow pathogen identification",
      "Failure of traditional pathogen identification methods",
      "Complexity of poly-microbial samples",
      "Lengthy sequencing file uploads",
      "Costly big data storage for sequencing files",
      "Unreliable or cluttered public DNA sequence databases (e.g., GenBank)",
      "Difficulty analyzing mixed chromatograms or InDel patterns",
      "Need to culture and separate samples before identification",
      "Inefficient manual review of microbial references"
    ],
    "solutionIntents": [
      "Rapid pathogen identification",
      "Sequence-based pathogen analysis",
      "Genomic diagnostics",
      "Microbial identification software",
      "NGS data analysis for pathogens",
      "Sanger data analysis for pathogens",
      "Curated microbial reference databases",
      "Cloud-based bioinformatics solutions for infectious disease",
      "Automated pathogen reporting",
      "Analysis of poly-microbial samples",
      "Infectious disease diagnostics using sequencing"
    ],
    "evaluationIntents": [
      "Pathogen identification software comparison",
      "NGS analysis tool review",
      "Sanger sequencing analysis solutions",
      "Microbial database accuracy and reliability",
      "Speed of pathogen detection platforms",
      "Cost of genomic analysis software for clinical use",
      "FDA breakthrough devices for pathogen detection",
      "Ripseq software capabilities and features",
      "Efficacy of sequencing-based pathogen identification versus traditional methods"
    ]
  },
  "businessProfileClaims": [],
  "timestamp": 1790423774523
}